Abstract

IntroductionA proliferation-inducing ligand (APRIL) from the TNF family, owing to its role in the generation and survival of plasma cells (PCs), is currently targeted for rheumatoid arthritis (RA) treatment. However, little is known about APRIL expression in RA lesions, hampering our understanding of the way APRIL may modulate this autoimmune disease.MethodsWe performed immunological staining of human normal, non-RA and RA synovial tissues with a pair of antibodies specifically recognizing APRIL-producing cells and secreted APRIL.ResultsWe detected significant amounts of secreted APRIL in normal synovium mostly concentrated around blood vessels and at the lining layer, but no cells producing APRIL. Meanwhile, we observed that blood neutrophils constitutively secrete APRIL, indicating that blood APRIL may diffuse into the synovium via its fenestrated vessels. Synovium from non-RA and RA patients retained similarly secreted APRIL, but in this case APRIL-producing cells, including neutrophils and macrophages, were present in the tissue. Notably, PCs - when present in RA synovium - accumulated in areas of APRIL retention, spreading from blood vessels towards the lining layer.ConclusionsPCs accumulate in synovial zones rich in secreted APRIL, consistent with a pro-survival role of APRIL for PCs in RA. The concentration of APRIL by normal synovium indicates that this tissue may constitute a proper environment for PCs even before RA onset.

Highlights

  • A proliferation-inducing ligand (APRIL) from the TNF family, owing to its role in the generation and survival of plasma cells (PCs), is currently targeted for rheumatoid arthritis (RA) treatment

  • Insert: Aprily-2 staining in the absence or presence of recombinant soluble A proliferation-inducing ligand (APRIL). (b) Normal synovium and non-inflamed tonsils were immunostained with control immunoglobulin (cIg), Aprily-2, and anti-heparan sulfate proteoglycans (HSPG)

  • The present study demonstrates that normal synovium and pathologic synovium both for non-RA and RA patients retain soluble APRIL, constituting APRIL-rich niches

Read more

Summary

Introduction

A proliferation-inducing ligand (APRIL) from the TNF family, owing to its role in the generation and survival of plasma cells (PCs), is currently targeted for rheumatoid arthritis (RA) treatment. APRIL promotes selectively the development of chronic lymphocytic leukemia [9] and diffuse large B-cell lymphoma [10]. This selectivity is consistent with the restricted expression of APRIL signaling receptors - the transmembrane activator, calcium modulator and cyclophilin ligand interactor (TACI, TNFSFR13), and the B-cell maturation antigen (BCMA, TNFSFR17) - to specific B-cell differentiation stages [11]. A subsequent phase I clinical trial with soluble TACI in RA

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call